X-linked lymphoproliferative syndrome associated with Epstein-Barr virus encephalitis and lymphoproliferative disorder

Takeo Mukai; Kenji Waki

doi:10.1002/ccr3.7949

X-linked lymphoproliferative syndrome associated with Epstein-Barr virus encephalitis and lymphoproliferative disorder

Clin Case Rep. 2023 Sep 22;11(9):e7949. doi: 10.1002/ccr3.7949. eCollection 2023 Sep.

Authors

Takeo Mukai¹, Kenji Waki²

Affiliations

¹ Department of Pediatrics The University of Tokyo Hospital Tokyo Japan.
² Department of Pediatrics Kurashiki Central Hospital Okayama Japan.

Abstract

When treating patients with EBV encephalitis, the possibility of XLP should be considered. Once the diagnosis of XLP is made, aggressive treatment such as rituximab, and other immunosuppressive agents are desired for rapid transition to HSCT.

Keywords: Epstein–Barr virus; X‐linked lymphoproliferative syndrome; hemophagocytic Lymphohistiocytosis; lymphoproliferative disorders; rituximab.

Publication types

Case Reports